Phase 1/2 ACRES Trial: Pioneering 225Ac-rhPSMA-10.1 for Post-Lutetium mCRPC

/in , , , /by

The ACRES trial represents a promising step forward in targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC), focusing on Actinium-225-labeled radiohybrid PSMA-10.1 (225Ac-rhPSMA-10.1) in patients who have largely progressed after Lutetium-177 PSMA therapy. This multi-site, open-label Phase 1/2 study addresses an urgent need in advanced prostate cancer, where effective post-Lu-PSMA options remain limited despite […]

Read more

EBNK-001: Pioneering Off-the-Shelf NK Cell Therapy for Solid Tumors

/in , , , /by

EBNK-001 represents a promising advancement in cancer immunotherapy as an “off-the-shelf” allogeneic natural killer (NK) cell product designed for multi-dose administration in patients with advanced solid tumors. Unlike autologous therapies that require individual patient cell harvesting and processing, EBNK-001 leverages healthy donor-derived NK cells, enabling immediate availability without lengthy manufacturing delays. This off-the-shelf approach addresses […]

Read more

FDA Clears Phase 2b Trial of Teverelix in Advanced Prostate Cancer Patients at High Cardiovascular Risk

/in , , /by

A new phase 2b clinical trial has received FDA “study may proceed” clearance for teverelix, a long‑acting GnRH antagonist being evaluated in men with advanced prostate cancer who are at high cardiovascular risk. The trial is designed to test a dose‑optimization regimen of teverelix over a 22‑week treatment period, with the primary goal of confirming […]

Read more

SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC)

/in , , , /by

A  first-in-human Phase 1/2 trial of SPR1020, a highly selective PARP1 inhibitor, dosed its inaugural patient, igniting hope for patients with advanced solid tumors harboring DNA repair deficiencies. This open-label, multicenter study employs a classic 3+3 dose-escalation design to pinpoint the recommended Phase II dose or maximum tolerated dose, transitioning seamlessly into expansion cohorts tailored […]

Read more

Alliance A222001 Phase 2 Trial: Oxybutynin Looks Promising for Hot Flashes in Men Under ADT

/in , , , , /by

The Alliance A222001 study, published in the Journal of Clinical Oncology in January 2026, found that oxybutynin, a drug typically used to treat overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy (ADT), with improvements occurring within the first week of treatment and sustained throughout the study period. The findings could reshape how […]

Read more

Phase 1/2 JASPER Trial: Ruxolitinib Plus Enzalutamide for mCRPC

/in , , , /by

The JASPER trial is a phase 1/2 study launching from the University of Michigan, takes a fundamentally different approach to castration-resistant prostate cancer by targeting the molecular machinery driving cancer plasticity from the start: the JAK/STAT inflammatory signaling axis. Understanding why this strategy makes biological sense requires stepping into what we now know about how […]

Read more

ANDROMEDA Trial: Alpha vs. Beta PSMA Therapy

/in , , /by

The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]

Read more

Preliminary Data From a Phase 1/2 Trial of PDS01ADC Plus Docetaxel in mCRPC

/in , , , /by

Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC  (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]

Read more

ARREST Trial: Precision Radiation Boosts to Fix 177Lu-PSMA’s 50% Failure Rate

/in , , /by

ARREST trial could change mCRPC treatment by solving 177Lu-PSMA’s biggest limitation: up to 50% of patients get little benefit despite FDA approval and proven survival gains. The simple idea? Add targeted external beam radiation boosts to the tumors that radioligand therapy misses, creating a hybrid approach that could cut skeletal complications dramatically. Current 177Lu-PSMA therapy […]

Read more

SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors

/in , , , /by

SL-28 is a new type of donor cell therapy called Leukocyte-Tells. These cells come from healthy donors and get prepared outside the body to better fight cancer. They make more cancer-killing compounds, eat tumor cells, release enzymes, produce helpful signals, and move well toward tumors. Unlike other cell therapies, SL-28 does not need to match […]

Read more